<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1139">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04565379</url>
  </required_header>
  <id_info>
    <org_study_id>Shaperon001</org_study_id>
    <secondary_id>2020-003107-34</secondary_id>
    <nct_id>NCT04565379</nct_id>
  </id_info>
  <brief_title>Clinical Trial to Investigate the Efficacy and Safety of NuSepin® in COVID-19 Pneumonia Patients</brief_title>
  <official_title>A Randomized, Double Blind, Placebo-controlled, Phase 2 Clinical Trial to Investigate the Efficacy and Safety of 2 Doses of NuSepin® Intravenous Infusion in COVID-19 Pneumonia Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shaperon</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shaperon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, double blind, placebo-controlled, phase 2 clinical trial to investigate the
      efficacy and safety of 2 doses of NuSepin® intravenous infusion in COVID-19 pneumonia
      patients
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 25, 2020</start_date>
  <completion_date type="Anticipated">November 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in Time to Clinical Improvement (TTCI) between the 2 treatments and the placebo group (in days)</measure>
    <time_frame>Day 29</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with CRP &lt; 10 mg/L or &lt; 30% decreases from baseline</measure>
    <time_frame>Day 15 and Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Status assessed by the six-category ordinal scale at fixed time points</measure>
    <time_frame>Day 1, 4, 9, 15 and 29</time_frame>
    <description>Minimum value being 1, Maximum value being 6. Smaller the number, better the clinical status &amp; outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to complete clinical remission OR NEWS2 (National Early Warning Score 2) of ≤ 2 maintained for 24 hours</measure>
    <time_frame>Up to Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>Up to Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration (days) of mechanical ventilation</measure>
    <time_frame>Up to Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration (days) of extracorporeal membrane oxygenation</measure>
    <time_frame>Up to Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration (days) of supplemental oxygenation</measure>
    <time_frame>Up to Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay (days)</measure>
    <time_frame>Up to Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of ICU stay (days)</measure>
    <time_frame>Up to Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of incidence of treatment emergent adverse events (TEAEs) in 3 treatment groups</measure>
    <time_frame>Day 15 and Day 29</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Serum level of TNF-α in pg/ml</measure>
    <time_frame>Day 0, 4, 9, 15 and 29</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Serum level of IL-1β in pg/ml</measure>
    <time_frame>Day 0, 4, 9, 15 and 29</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Serum level of IL-6 in pg/ml</measure>
    <time_frame>Day 0, 4, 9, 15 and 29</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Serum level of IL-8 in pg/ml</measure>
    <time_frame>Day 0, 4, 9, 15 and 29</time_frame>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>COVID19 Pneumonia</condition>
  <arm_group>
    <arm_group_label>NuSepin® 0.1 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>NuSepin® 0.1 mg/kg in 100 ml normal saline infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NuSepin® 0.2 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>NuSepin® 0.2 mg/kg in 100 ml normal saline infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>100 ml normal saline infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NuSepin® 0.1 mg</intervention_name>
    <description>NuSepin® 0.1 mg</description>
    <arm_group_label>NuSepin® 0.1 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NuSepin® 0.2 mg</intervention_name>
    <description>NuSepin® 0.2 mg</description>
    <arm_group_label>NuSepin® 0.2 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Normal Saline</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female subjects aged between 18≤ and &lt;80 years old

          2. Laboratory-confirmed SARS-CoV-2 infection by PCR test for the first time within 144
             hours prior to randomization

          3. Diagnosis of pneumonia based on:

               -  Radiographic infiltrates by imaging (chest x-ray, CT scan) AND

               -  3 of the following clinical symptoms: new onset cough, fever, fatigue, sputum
                  (all day), tachypnea, dyspnea, pleuritic chest pain AND

               -  CRP value &gt; 10 mg/L

          4. Patients with blood leukocyte count &gt; 4.0 x 109 /L and lymphocyte count &gt; 0.7 x 109 /L

          5. Patients with SpO2 ≤ 94% on room air or Pa02/FI02 ratio &lt; 300mgHg at screening

          6. Patients capable to give consent and who have signed the informed consent form before
             any trial related assessment.

          7. Medically accepted effective contraception for women of childbearing potential (WOCBP)
             which should be continued until at least 90 days after the last dose of trial
             treatment.

        Exclusion Criteria:

          1. Alanine Transaminase (ALT) or Aspartate Transaminase (AST) &gt; 5 times the upper limit
             of normal.

          2. Reduced renal function with estimated glomerular filtration rate (eGFR) &lt; 30 ml/min or
             hemodialysis or hemofiltration.

          3. Pregnancy or breast feeding.

          4. Evidence of multiorgan failure

          5. Steroid treatment by any reason within 72 hours prior to enrolment

          6. Participation in any other clinical trial of an experimental agent treatment for
             COVID-19

          7. Physician makes a decision that trial involvement is not in patients' best interest,
             or any condition that does not allow the protocol to be followed safely.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Seung-Yong Seong, Dr.</last_name>
    <role>Study Chair</role>
    <affiliation>Shaperon Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David Song</last_name>
    <phone>+82-2-6083-8318</phone>
    <email>shsong@shaperon.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>&quot;Leon Daniello&quot; Clinical Hospital of Pneumophtisiology Cluj-Napoca Pneumology Clinic</name>
      <address>
        <city>Cluj-Napoca</city>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cosmina Magdau, Dr.</last_name>
      <email>cmagdau@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Hospital for Infectious Diseases and Pneumophtisiology &quot;Victor Babes&quot;, Craiova Infectious Diseases Clinic for Adults</name>
      <address>
        <city>Craiova</city>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Iulian Diaconescu, Dr.</last_name>
      <email>diaconescu_ig@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>&quot;Sf. Parascheva&quot; Infectious Diseases Clinical Hospital Iasi Infectious Diseases Department</name>
      <address>
        <city>Iaşi</city>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catalina Luca, Dr./Prof.</last_name>
      <email>catalina_luca2006@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>&quot;Sf. Ioan cel Nou&quot; Suceava County Emergency Hospital Infectious Diseases Department</name>
      <address>
        <city>Suceava</city>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olga Caliman-Sturdza, Dr.</last_name>
      <email>sturdza_olga@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Romania</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 23, 2020</study_first_submitted>
  <study_first_submitted_qc>September 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 25, 2020</study_first_posted>
  <last_update_submitted>September 27, 2020</last_update_submitted>
  <last_update_submitted_qc>September 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

